EAACI Congress 2025 Back

13 - 16 June 2025 Glasgow, United Kingdom

Marc A. Riedl

United States of America

Marc A. Riedl

Sessions

Friday 13 Jun

10:57 - 11:09 Improvements in Quality of Life in Patients With Hereditary Angioedema Receiving Donidalorsen: Post Hoc Analysis From the OASIS-HAE Study and Results From the OASISplus Open-Label Extension

Saturday 14 Jun

12:00 - 13:00
SAT14 CSL Behring - Changing the flow: Shifting HAE treatment toward normalization of patients’ lives Sponsored Sessions Meeting Academy M1

12:00 - 12:05 Introduction

12:05 - 12:25 Navigating troubled waters: Barriers to the improvement of QoL for patients with HAE

12:50 - 13:00 Q&A - Session

10:10 - 10:17 The impact of treatment switching on healthcare resource utilization among patients with hereditary angioedema in the United States

09:36 - 09:48 Sebetralstat for Treatment of HAE Attacks in Patients Receiving Berotralstat, Lanadelumab, or C1 Inhibitor for Long-term Prophylaxis: Interim Analysis from KONFIDENT-S

EAACI Congress 2025 Back

Sessions

Share this pen